Recommended Timing for Chemotherapy Not Linked With Lower Death Risk in Ovarian Cancer

November 20, 2018

Meeting the ovarian cancer quality indicator of administering chemotherapy within 42 days of cytoreductive surgery is not associated with improved survival in patients, according to a study published online in Gynecologic Oncology.

The study highlights the “importance of validating quality measures before implementation,” according to the paper.

Researchers tapped the database at a National Cancer Institute-designated Comprehensive Cancer Center and analyzed time to chemotherapy for 635 women who received adjuvant chemotherapy for epithelial ovarian/fallopian tube/peritoneal cancer.

Among the patients, 59.1% received chemotherapy within 42 days of cytoreductive surgery.

“The time to chemotherapy interval of within 42 days was not strongly associated with improved survival, particularly when age, stage of disease, insurance enrollment and surgical characteristics were taken into account,” researchers reported.

The relationship between time to chemotherapy and survival did not vary among patients who received primary debulking surgery, interval debulking surgery, or residual disease status.

Jolynn Tumolo

For articles by First Report Managed Care, click here

To view the First Report Managed Care print issue, click here